Abstract: Methods for transdermal delivery of glycosaminoglycans (GAGs) are disclosed, comprising applying ultrasound to the skin followed by topical administration of one or more GAGs optionally complexed with a polysaccharide carrier. When GAG is hyaluronic acid complexed with a modified starch, a transdermal delivery method is provided for facilitating delivery of high molecular weight hyaluronic acid into deep layers of the epidermis and to the dermis in a non-invasive, convenient and painless way. This transdermal delivery method may be applied in treatment of skin aging phenomena associated with collagen and/or hyaluronic acid depletion or loss.

Abstract: A controlled release system including surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition including the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

Abstract: Stable and durable polymeric microbubbles of a 1-10 ?m size range are disclosed. The microbubbles are synthesized from the co-polymer poly lactic-co-glycolic acid (PLGA), which provides a plurality of PLGA microbubbles presenting diverse cavitation activities. The PLGA microbubbles are particularly suitable for cavitation enhancement purposes and are applicable in various clinical procedures such as ablation or enhancement of uptake of chemical or biological therapy in cells and tissue.

Abstract: Provided herein methods for treating a subject suffering from a disease or a disorder associated with hyperproliferating cells, by irradiating the cells with low-frequency ultrasound at an intensity that is either below the cavitational threshold intensity for the ultrasound frequency, or is characterized by a low-frequency mechanical index below 2.5. The methods may further comprise determining an elasticity value of the cells, and adjusting the ultrasound intensity accordingly.

Abstract: A controlled release system including surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition including the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

Abstract: A controlled release system includes surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition includes the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

Abstract: A controlled release system includes surfactant protein D (SPD) and a carrier suitable for controlled release that can be polylactic-co-glycolic acid (PLGA). The system can be in the form of a nanoparticle. A pharmaceutical composition includes the system and a pharmaceutically acceptable carrier. Methods of treatment of a disease, disorder or condition associated with a decreased level of SPD in a subject, or for pulmonary delivery of SPD, include administering the pharmaceutical composition to a subject in need of such treatment.

Abstract: The use of at least one modified polysaccharide selected from starch, amylose, amylopectin and dextrin or a mixture thereof substituted with one or more amine and/or ammonium groups, as an antimicrobial agent, is provided by the present invention, as well as compositions comprising a polymer material blended with the modified polysaccharide. Also provided by the present invention are antimicrobial articles produced from the compositions of the invention and antimicrobial surface, fabric, foam or sponge produced by coating, soaking or dipping in a solution comprising modified polysaccharides. The present invention further provides non-therapeutic methods for killing microorganisms, inhibiting their growth, and/or preventing formation of a biofilm, and for producing an antimicrobial surface, article, fabric, foam or sponge from modified polysaccharides.

Abstract: The present invention provides a complex comprising at least one phosphoinositide and at least one positively charged modified polysaccharide, pharmaceutical compositions comprising the complex, methods for treatment of a disease, disorder or condition associated with impaired phosphoinositide-mediated signaling comprising administering the complex to an subject in need, and methods for delivery of a phosphoinositide into cells, comprising contacting the cells with the complex of the invention.

Abstract: A complex includes RNA and a positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin. The complex can be formed into a pharmaceutical composition. The complex can be used in methods for RNA transfection, gene therapy and treatment of a disease, disorder or condition. The positively charged modified polysaccharide can be used in connection with RNA transfection into cells.

Abstract: Charged nanostructure being comprising gold nanoparticle which may bear on at least portion thereof a positively charged polymer wherein the positively charged polymer may bearon at least portion thereof a negatively charged polymer is disclosed. Uses thereof for diagnosis is also disclosed.

Abstract: A complex includes RNA and a positively charged modified polysaccharide selected from starch, amylose, amylopectin, galactan, chitosan, or dextrin. The complex can be formed into a pharmaceutical composition. The complex can be used in methods for RNA transfection, gene therapy and treatment of a disease, disorder or condition. The positively charged modified polysaccharide can be used in connection with RNA transfection into cells.